- Annovis Bio ( NYSE: ANVS ) said it had begun patient enrollment for its ongoing Phase 3 study of its drug, buntanetap, to treat Parkinson's disease.
- The company expects interim data analysis from the study in the second quarter.
- Patients are being treated with 10mg, 20mg of the therapy or placebo, on top of their standard of care, for six months.
- The company's Phase 3 trial in Parkinson's disease builds upon earlier data from a Phase 2a study which demonstrated that patients treated with buntanetap showed statistically significant improvements in both motor function and coding speed.
For further details see:
Annovis Bio begins phase 3 study of Buntanetap to treat Parkinson's disease